Abstract Details

Title Prospective Analysis of Cerebrospinal Fluid Protein Levels Reveals Candidate Biomarkers for Disability Outcome in Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P15 - Poster Session 15 (12:00 PM-1:00 PM)

Poster/Presentation
Number 9-020

Objective The aim of the study was to reveal prognostic cerebrospinal fluid (CSF) protein biomarkers in our multiple sclerosis (MS) cohort.

Background We previously identified CSF proteins with differential levels and affected pathways in MS and MS subgroups. Here, we prospectively analyzed the proteome data after a 10-year follow-up to identify candidate disability markers.

Design/Methods Clinical information of 200 patients included in the previous study was reviewed and patients were assigned into two groups based on the following criteria: Group I consisted of patients with a minimum of 10-year follow-up and a final Expanded Disability Status Scale (EDSS) score lower than 3 (N=34). Group II consisted of patients with primary or secondary progressive course with a worsened disability level of EDSS≥5 during the follow-up (N=18). A total of 121 proteins with altered levels in one or more patients of Group I or II in the initial analysis were included in the analysis. Mean fold-changes compared to non-MS controls (N=22) were compared by a two-tail t-test between the two groups.

Results There were 24 proteins with significantly different levels between the two groups (P<0.05). Among them, 13 proteins showed no change in one of the groups, while showing at least 1.3-fold change in the other group. The best candidate markers determined based on the significance and fold-change pattern were: SH3BP-1, IFIT-3, haptoglobin, Zn-alpha-2-glycoprotein, VAMP-2, transmembrane protein 95, CELF-2, Annexin-4, C1 Inh, nucleolin, contactin-1, VDB, myosin XVBP. Pathway analysis with candidate proteins resulted in significant enrichment of the platelet degranulation pathway.

Conclusions This prospective proteomic analysis revealed candidate CSF biomarkers which may predict long-term disability outcomes of MS patients. A larger study group is needed to verify whether the candidate proteins show any correlation with demographic and clinical factors such as sex, age at MS onset, good or bad recovery from the relapses, and initial lesion topography.

Authors/Disclosures
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine) PRESENTER	Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.
Elif Everest, PhD (National Institutes of Health)	Ms. Everest has received personal compensation in the range of $50,000-$99,999 for serving as a postdoctoral visiting fellow with National Institutes of Health.
Ugur Uygunoglu (Cerrahpasa)	Ugur Uygunoglu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Turkey . The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec/Gen Pharma of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck-Serono of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanovel of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genveon of Turkey.
	No disclosure on file
Alper Bulbul	Alper Bulbul has nothing to disclose.
Melih Tutuncu, MD	No disclosure on file
Sabahattin Saip	Sabahattin Saip has nothing to disclose.
	No disclosure on file
Eda Turanli	The institution of Eda Turanli has received research support from Scientific and Technological Research Council of Turkey (TÜBITAK). The institution of Eda Turanli has received research support from Turkish MS Society. The institution of Eda Turanli has received research support from Acibadem University Scientific Research Projects Commission . The institution of Eda Turanli has received research support from Istanbul University Scientific Research Projects Commission .

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details